$92.28 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter

Equities research analysts predict that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will announce $92.28 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Ironwood Pharmaceuticals’ earnings, with the highest sales estimate coming in at $95.81 million and the lowest estimate coming in at $88.22 million. Ironwood Pharmaceuticals posted sales of $86.83 million in the same quarter last year, which would indicate a positive year over year growth rate of 6.3%. The business is scheduled to report its next quarterly earnings report on Tuesday, November 6th.

On average, analysts expect that Ironwood Pharmaceuticals will report full-year sales of $338.40 million for the current financial year, with estimates ranging from $327.55 million to $349.78 million. For the next year, analysts forecast that the business will post sales of $433.43 million, with estimates ranging from $375.40 million to $530.18 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.18). The business had revenue of $68.69 million for the quarter, compared to analyst estimates of $93.48 million. The firm’s revenue was down 20.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.18) earnings per share.

Several brokerages have recently commented on IRWD. BidaskClub downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 26th. Wells Fargo & Co set a $23.00 price objective on shares of Ironwood Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 8th. HC Wainwright set a $13.00 price objective on shares of Ironwood Pharmaceuticals and gave the company a “sell” rating in a research note on Wednesday, October 31st. ValuEngine downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 31st. Finally, Cowen reaffirmed a “market perform” rating on shares of Ironwood Pharmaceuticals in a research note on Wednesday, July 18th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $18.44.

Ironwood Pharmaceuticals stock opened at $12.78 on Wednesday. The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of -13.74 and a beta of 1.33. Ironwood Pharmaceuticals has a twelve month low of $12.67 and a twelve month high of $21.20.

In related news, insider Mark G. Currie sold 130,000 shares of the business’s stock in a transaction dated Thursday, August 23rd. The shares were sold at an average price of $18.45, for a total transaction of $2,398,500.00. Following the transaction, the insider now owns 791,666 shares in the company, valued at $14,606,237.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Julie Mchugh sold 1,500 shares of the business’s stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $19.10, for a total transaction of $28,650.00. Following the transaction, the director now owns 91,131 shares in the company, valued at approximately $1,740,602.10. The disclosure for this sale can be found here. Insiders have sold 248,339 shares of company stock worth $4,475,466 in the last quarter. 7.63% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Meeder Asset Management Inc. purchased a new position in shares of Ironwood Pharmaceuticals during the second quarter valued at about $186,000. A.R.T. Advisors LLC purchased a new position in shares of Ironwood Pharmaceuticals during the first quarter valued at about $208,000. V Wealth Management LLC purchased a new position in shares of Ironwood Pharmaceuticals during the second quarter valued at about $258,000. PNC Financial Services Group Inc. increased its position in shares of Ironwood Pharmaceuticals by 17,621.9% during the second quarter. PNC Financial Services Group Inc. now owns 17,013 shares of the biotechnology company’s stock valued at $325,000 after buying an additional 16,917 shares during the period. Finally, Amalgamated Bank increased its position in shares of Ironwood Pharmaceuticals by 17.4% during the second quarter. Amalgamated Bank now owns 21,156 shares of the biotechnology company’s stock valued at $405,000 after buying an additional 3,142 shares during the period. Institutional investors own 97.29% of the company’s stock.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

Recommended Story: What do investors mean by earnings per share?

Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply